摘要
铁是细胞生长增殖和机能活动所必需的元素之一。绝大多数细胞包括肿瘤细胞在内摄取铁主要通过转铁蛋白受体(transferrin receptor,TfR)介导。研究显示,转铁蛋白受体在肿瘤细胞表面高表达,因而可与多种物质联合应用于恶性肿瘤的治疗。本文从转铁蛋白受体结合药物(青蒿素、多柔比星和藤黄酸等)、基因、抗体、聚乙二醇、纳米方面对近年来转铁蛋白受体在血液系统恶性肿瘤治疗方面的研究进展进行了综述。
Iron is one of the necessary elements for cell growth, proliferation and functional activities. Iron uptake of the vast majority cells, including tumor cells, is primarily mediated by transferrin receptor （TfR）. Studies showed that transferrin receptor expressed on tumor cell surface at a high level, thus can be used in the treatment for malignant tumor combined with many kinds of materiaes. In this article, recent progress of study on transferrin receptor used in treating hematological malignant tumor are reviewed from aspects of transferrin receptor combined with drugs including atem sinin, doxorubicin, gambogic acid and so on, genes, antibodies, polyethylene glycol and nanoparticles.
出处
《中国实验血液学杂志》
CAS
CSCD
2010年第1期273-276,共4页
Journal of Experimental Hematology
基金
国家863项目
编号2007AA02007
国家自然科学基金
编号30872970
